WO1994004556A1 - Aminofurostenes, compositions, et procedes d'utilisation - Google Patents

Aminofurostenes, compositions, et procedes d'utilisation Download PDF

Info

Publication number
WO1994004556A1
WO1994004556A1 PCT/US1993/007810 US9307810W WO9404556A1 WO 1994004556 A1 WO1994004556 A1 WO 1994004556A1 US 9307810 W US9307810 W US 9307810W WO 9404556 A1 WO9404556 A1 WO 9404556A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino
furost
cholesterol
cyclodextrin
compound
Prior art date
Application number
PCT/US1993/007810
Other languages
English (en)
Inventor
Norman B. Javitt
Original Assignee
New York University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York University filed Critical New York University
Priority to AU50815/93A priority Critical patent/AU5081593A/en
Publication of WO1994004556A1 publication Critical patent/WO1994004556A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring

Definitions

  • This invention relates to amino-substituted furostenes, and derivatives and analogs thereof, including compositions and methods of making and using these compounds.
  • Cholesterol can prevent a reduction in the fluidity of cells and tissues by preventing the fatty acyl chains of the membrane lipids from binding with each other. See, e.g., Darnell, et al. , Molecular Cell Biology, Scientific American Books, New York: 576-577 (1986) . Cholesterol synthesis occurs according to an enzyme-mediated biosynthetic pathway, in which the rate limiting enzyme is believed to be hydroxymethylglutaryl-Co-A reductase
  • HMG-CoA reductase HMG-CoA reductase
  • arteriosclerosis a disease of the arteries, the most important type of which is atherosclerosis, which is character ⁇ ized by an abnormal hardening and thickening of the arterial walls due to the accumulation and deposition of fatty materials, including cholesterol.
  • Atherosclerosis in turn, can lead to thrombosis and infarction, and is involved in several other related diseases, including hypertension, hypothyroidism, obstructive jaundice, nephrosis, diabetes mellitus, pancreatitis, multiple myeloma, porphyria and obstructive liver disease. See, e.g., The Merck Manual 15th edition, Chs. 85 and 25-30 (1987) .
  • HMG-CoA reductase Although it was initially thought that the amount of cholesterol in tissues regulated its own production, more recent evidence indicates that certain precursors and metabolites of cholesterol are much more potent inhibitors of the rate-limiting enzyme HMG-CoA reductase. Many of these potent inhibitors have been classified as "oxysterols" such as 25-hydroxycholesterol and 26-hydroxycholesterol. The latter compound was previously shown to be naturally occurring and also to be an inhibitor of HMG-CoA reductase. See, e.g., Javitt, U.S. Patent No. 4,427,668. The product 26-aminocholesterol was also found to be an even more potent inhibitor of HMG-CoA reductase. See, e.g., Javitt, U.S.
  • Patent No. 4,939,134 It should also be noted that there is no reliable correla ⁇ tion between liver or plasma cholesterol levels and the amount of HMG-CoA reductase and LDL receptor binding.
  • the known drug mevinolin has been observed to inhibit hepatic cholesterol synthesis even though it increases the amount of HMG-CoA reductase.
  • the enzyme is less active in the presence of the drug, which is believed to modify mevinolin' s three-dimen ⁇ sional conformation. From cell culture studies it is known that this drug (and others) also upregulates LDL receptors in fibroblasts and other non-hepatic cells.
  • 26-hydroxycholesterol and 26-amino-cholesterol have been found to inhibit HMG-CoA reductase activity in fibroblasts and reduce LDL binding, thereby decreasing the rate at which tissue cells can produce and accumulate cholesterol . See also, Javitt et al J. Lipid Res. , 26:950-954 (1985) ; Lorenzo et al FEBS Letters 218:77-80 (1987) ; and U.S. Patent No. 4,939,134.
  • the drugs currently in use for the inhibition of cholesterol synthesis have an impact primarily on the liver, and are believed to function by causing upregulation of the LDL receptors of the liver (to increase liver uptake of cholesterol and decrease serum levels) or by inhibiting HMG-CoA reductase, so that cholesterol production is reduced.
  • 26-hydroxycholesterol and 26-aminocholesterol have been found to inhibit HMG-CoA reductase activity in fibroblasts and reduce LDL binding, thereby decreasing the rate at which tissue cells can produce and accumulate cholesterol. See Javitt et al J. Lipid Res. , 26: 950-954 (1985) ; Lorenzo et al FEBS Letters 218:77-80 (1987) ; and U.S. patent No. 4,939,134.
  • Mevinolin which is an allosteric inhibitor of HMG-CoA reductase, achieves this regulation effect by inhibiting cholesterol synthesis in the liver. This stimu ⁇ lates increased LDL receptor activity in the liver, causing hepatic uptake of cholesterol, which in turn reduces plasma cholesterol. Cholestyramine increases the need for bile acid synthesis from cholesterol in the liver, which in some individu- als will result in upregulation of LDL receptors.
  • Drugs like cholestyramine are not absorbed in the intestine and also bind numerous other drugs used for cardiovascular diseases (such as chlorothiazide, phenylbutazone, phenobarbital, anticoagulants, digitalis) as well as fat soluble vitamins (A, D, E and K) . Consequently, these drugs and vitamins must be taken before and after administration of cholestyramine, or the effect of these drugs or vitamins is lost. Accordingly, it would be preferable to have an alternative drug to cholestyramine that acts systemically and does not deplete the body of concomitantly administered drugs, as well as fat-soluble vitamins. See Goodman and Gilman, supra, at 834-847.
  • Diosgenin a natural plant sterol
  • Diosgenin is the starting material for the production of many different synthesis sterols used as drugs.
  • a 5th ring referred to as a furane ring
  • a 6th ring that can be referred to as a spiroketal ring
  • Virtually all- steroids used as medications that are produced from diosgenin require elimina- tion of the 5th and 6th ring and shortening of the hydrocarbon side chain. Opening of the 6th ring only has not been taught or suggested for use as a drug.
  • patent No. 3,723,4108 discloses the production of 17/5-hydroxy-androstanes by treating an ⁇ _, -oxido-steroid ketone with triakylstannine in the presence of UV light and a suitable solvent using diosgenin as a starting material. While Pettit and Bowyer, J. Amer. Chem. Soc. 25:84-86 (1960) discloses the opening of ring 6 of a diosgenin to form 3j ⁇ -acetoxy-5-furostene-26-ethylenethioketal, this and related compounds are not taught or suggested to be used as a drug, nor are amino substituted furostene compounds taught or suggested.
  • Yet another object of the present invention is to provide compounds, compositions and methods for the prevention and treatment of atherosclerosis and other diseases associated with excessive cholesterol uptake, accumulation and/or synthesis, by administering an effective cholesterol-inhibiting amount of an aminofurostene, and a pharmaceutically acceptable carrier.
  • a further object of the present invention is to provide compounds, compositions and methods for regulating cholesterol synthesis, uptake, and accumulation in a subject, including a mammal or a bird, such as a human.
  • a further object of the present invention is to provide pharmaceutical preparations containing 26-aminofurostenes according to formula (I) in an amount sufficient for use in one or more of the embodiments of this invention.
  • aminofuro ⁇ stene compounds are provided according to formula (I) :
  • R 1 is hydroxy or keto, such that at least one of C3 and C4 and C4 and C5 form a double bond when R 1 is keto and C5 and C6 form a double bond when R 1 is hydroxy;
  • R 2 is sulfur, oxygen or nitrogen; and
  • R 3 is a C1-C3 alcohol, aldehyde or acid, or a pharmaceutically acceptable ester, ether, sulfate, carbonate, glucuronide, cyclodextrin complex or salt thereof, which compounds provide inhibitory effects on the uptake, synthesis and/or accumulation of cholesterol in cells and/or tissues of an animal.
  • R 1 is hydroxyl.
  • R 2 is oxygen.
  • R 5 is selected from a methyl, a methyl alcohol, a formaldehyde and a formic acid.
  • Compounds according to formula (I) can be selected from substituted 26-amino-furost-5-en-3 -ols, and substituted and unsubstituted 26 -amino- furost- 5 - en- 3 ⁇ - o 1 s , 26-amino-furost-4-en-3-ones, 26-amino-furost- 4, 6-dien-3-ones, wherein 26-amino-furost-5-en-3/3-ol is more preferred.
  • a pharmaceutical composition comprising a compound according to formula (I) , or a pharmaceutically acceptable ester, ether, sulfate, carbonate, glucuronide or salt thereof, and a pharmaceutically acceptable carrier.
  • a pharmaceutical composition of the present invention further comprises a drug selected from a cardiac glycoside, an antidys- rythinic, a diuretic, an antihypertensive, an antianginal, an anticoagulant, and a lipid lowering agent.
  • a method for inhibiting cholesterol by reducing the rate of cholesterol synthesis uptake or accumulation by cells or tissue in an animal comprising administering an effective cholesterol inhibiting amount of a pharmaceutical composition comprising a compound according to formula (I) .
  • the composition is administered to provide the compound in an amount ranging from about 0.1 to 3 mg/kg, and also preferably in an amount ranging from about 0.15 to 1 mg/kg per 24 hour period.
  • the animal is selected from a mammal and a bird, and, more preferably the mammal is a human.
  • a method for treating a patient suffering from a pathology involving elevated cholesterol synthesis uptake or accumulation in cells or a tissue of a subject, comprising administering to the subject an amount effective to inhibit the cholesterol synthesis uptake or accumulation of a pharmaceutical composition comprising a compound according to formula (I) .
  • the pathology is selected from arteriosclerosis, atherosclerosis, hypertension, hypothyroidism, obstructive jaundice, nephrosis, diabetes mellitus, pancreatitis, multiple myeloma, porphyria and obstructive liver disease.
  • the present invention relates to substituted and unsubsti- tuted 26-amino-substituted furostenes. Additionally, the present invention relates to compositions and methods of making and using these compounds. These compounds have been unexpectedly discovered to provide anti-cholesterol activity, by inhibiting cholesterol uptake, synthesis and/or accumulation in cells and tissues of an animal, such as a human.
  • novel set of 26-aminofurostene compounds in accordance with the present invention have been discovered that have useful therapeutic properties.
  • 26-aminofurostene compounds according to the present invention include compounds according to formula (I) :
  • R 1 is hydroxy or keto, such that at least one of C3 and C4 and C4 and C5 form a double bond when R 1 is keto and C5 and C6 form a double bond when R 1 is hydroxy;
  • R 2 is sulfur, oxygen or nitrogen; and
  • R 3 is a C1-C3 alcohol, aldehyde or acid, or a pharmaceutically acceptable ester, ether, sulfate, carbonate, glucuronide, cyclodextrin complex or salt thereof, which provide inhibitory effects for the synthesis and/or accumulation of cholesterol in cells and/or tissues of an animal.
  • 26-aminofurostene compounds of the present invention according to formula (I) may also include mono and di-esters, sulfates, carbonates, glucuronides and ether or fluoro substitu ⁇ tions of such 26-aminofurostenes, which can be readily prepared according to known method steps of pharmaceutical technology, based on the teaching and guidance presented in the present specification. See, e.g., The U. S . Pharmacopeia, the National Formulary, 22nd Edition, U.S. Pharmacopeial Convention, Inc., Rockville, Maryland, and Suppl. 1-6, (1989); and Parrott, Pharmaceutical Technology, Burgess Publ. Co., Minneapolis, Minn. (1970) .
  • the C3-C5 and C5-C6 containing cyclic rings can be cyclohexane or cyclohexene, wherein (a) R 1 is hydroxy or keto, such that at least one of C3 and C4 and C4 and C5 form a double bond when R 1 is keto and C5 and C6 form a double bond when R 1 is hydroxy; (b) R 2 is sulfur, oxygen or nitrogen; and (c) R 3 is a C1-C3 alcohol, aldehyde or acid, or a pharmaceutically acceptable ester, ether, sulfate, carbonate, glucuronide, cyclodextrin complex or salt thereof, to provide aminofurost-5-enes, aminofurost-4-enes, and aminofurost- 4-,6-dienes, according to formula (I) .
  • aminofurostenes of the present invention also include 3-keto and 3 -hydroxy alkyl-substituted aminofurostenes, wherein the 27-methyl group can be an alcohol, an aldehyde or an acid, such that R 3 is a C1-C3 alkyl, alcohol, aldehyde or acid.
  • aminofurostenes of the present invention can include 26-aminofurostene compounds having substituted 28-methyl or 28-ethyl groups, wherein R 3 is a C2-C3 alkyl, alcohol, aldehyde or acid, including an ethyl or propyl alcohol, aldehyde or acid. It is preferred that R 1 is hydroxyl such that C5 and C6 form a double bond, as in aminofurost-5-ene-3-ols .
  • 26-aminofurostenes of the present invention include sulfur and nitrogen substitutions for oxygen, in the heterocyclic ring, wherein R 2 is preferably oxygen, but where R 2 can also be sulfur or nitrogen.
  • Preferred compounds according to formula (I) can be selected from alkyl substituted 26-amino-furost-5-en- 3/3-ols, unsubsti- tuted or alkylsubstituted 26-amino-furost- 5-en-3 ⁇ -ols, substi ⁇ tuted or unsubstituted amino-furost- 4-en-3-ones, and unsubsti- tuted or alkylsubstituted 26- amino-furost-4, 6-dien-3-ones, which compounds can include but are not limited to a compound selected from 26-amino-furost-5-en-3/3-ol, 26-amino-furost-5-en-3 ⁇ _-ol, 26-amino-furost-5-en-27, 3/3-diol, 26-amino-furost-5-en- -27, 3/3-diol, 26-amino-furost-5-en-27-al-33-ol, 26-amino-furost-5
  • Such compounds according to formula (I) are structurally analogous to oxysterols that repress HMG-CoA reductase, but are sufficiently dissimilar as to be unpredictable in their biologi ⁇ cal properties, such as the inhibition of cholesterol biosynthe ⁇ sis.
  • Such furostene compounds according to the present invention have been discovered to provide unpredictable results involving cholesterol inhibition, including inhibition of cholesterol uptake, synthesis and/or accumulation in vivo and in si tu, in comparison to naturally occurring oxygenated or hydroxy steroids.
  • 26-aminofurostene compounds of the present invention have been discovered to protect cells from the accumulation of cholesterol irrespective of the plasma cholesterol level, as well as inhibiting uptake and synthesis of cholesterol.
  • Aminofurostene compounds of the present invention can also be used therapeuti- cally, either alone or in combination with other drugs and/or pharmaceutical carriers, as a means for regulating cholesterol levels or for preventing and treating diseases related to abnormal cholesterol synthesis, uptake and accumulation.
  • amino-furost-5-en-3/3-ol has been found to inhibit de novo cholesterol synthesis in human hepatocytes, as presented herein.
  • 26-amino-furostene-3-ol 26-aminofurostene-3-ones, converted from the above-described synthesis of 26-amino-furostene-3-ols, can readily be formed by known methods, such as by the use of chromic acid, such as 26- amino-furost-4-ene-3-ones or 26-amino-furost-4, 6-diene-3-ones .
  • the above scheme can also take into account the presence of additional hydroxy, aldehyde, acid (such as 27-, 28-, or 29- OH, -al, or -oic) or alkyl groups which are protected
  • the 27-, 28-, or 29-acid substituents can be reacted with an alcohol to form the acetate protecting group.
  • Compounds according to formula (I) can inhibit cholesterol uptake, accumulation and synthesis, e.g., by acting as a downregulator of LDL receptors and consequently as an inhibitor of the rate-limiting enzyme HMG-CoA reductase.
  • the bio- isosteric substitution of an amino group at a terminal aliphatic carbon (as in formula (I) ) and preferably the N-26 position of a sterol with a five carbon side chain, provides a marked increase in capacity to interact with specific configurations on a cytostolic oxysterol carrier protein that is believed to participate in the biosynthetic pathway for cholesterol produc- tion.
  • compounds according to formula (I) of the present invention can be provided as a pure compound, or as mono and di-esterified derivatives and other pharmaceutically acceptable derivatives thereof, such as mono and di-ethers, and especially complexed with cyclodextrin, wherein 2 - hydroxyp ropy1 - ⁇ - cyc 1 odext rin and 2-hydroxypropyl -y-cyclodextrin are preferred.
  • Cyclodextrin-- aminofurostane complexes can be formed by adding the cyclodextrin in a 20-60% aqueous solution to one or more 26-aminofurostenes of the present invention, and letting the mixture stand for 12 to 72 hours, e.g., 24 hours, such that the aminofurostene molecules are partially enclosed by the cyclodextrin molecules.
  • Such complexes can have a maximum solubility of about 5-30 mg/ml of aqueous aminofurostene, such as 5, 7, 10, 12, 15, 16, 17, 18, 19, 20, 21, 22, 23, 25, 27, 28 or 30 mg/ml, depending on the cyclodextrin, aminofurostene and solubilization conditions used.
  • Cyclodextrins which can be used in 26-aminofurostene containing compositions of the present are preferably those that: provide sufficient solubility for administration to subjects to
  • Such preparation can be provided by mixing a 20-60% aqueous solution of a cyclodextran with a 26-aminofurostene compound according to formula (I) , in a final concentration of about 5 to 30 mg/ml, and letting the solution stand for 12-72 hours until the cyclodextran molecules have sufficiently associated with the molecules of a compound according to formula (I) to become soluble to substantially remain in solution at a temperature selected from about room temperature (e.g., 18-28 °C) to about 40"C.
  • room temperature e.g., 18-28 °C
  • 26-amino-furost-5-en-3/3-ol has a maximum, stable solubility of 20 mg/ml as a 45% aqueous solution of 2-hydroxypropyl-/3-cyclodextrins at about room temperature to about 39°C.
  • the cyclodextrin can be selected from a naturally occurring or chemically modified cyclodextrin. Naturally occuring cyclodextrins include, e.g., a- , ⁇ - , and y -cyclodextrins.
  • Chemically modified cyclodextrins can be selected from a methyl cyclodextrin, a hydroxyethyl cyclodextrin, a 2-hydroxypropyl cyclodextrin, a glucosyl cyclodextrin and a maltosyl cyclodextrin.
  • 2-hydroxypropyl- ⁇ - and 2-hydroxypropyl-7-cyclodextrans are preferred, and more preferably, 2-hydroxypropyl- ⁇ -cyclodextrans.
  • Cyclodextans useful for compositions of the present invention are readily made by known methods and are also available from commerical sources, such as MOLECULSOL ® , from Pharmatec (Lathua, Florida) .
  • cyclodextrins as presented herein
  • naturally occurring fatty acids, or other organic or inorganic esters can be formed using known pharmaceu- tically acceptable substituents, such as sulfates, carbonates and glucuronides .
  • Esterification and/or etherification can be at the 3- and/or 26-, 27-, 28-, and 29- positions.
  • Aryl and/or alkyl ethers such as methyl, ethyl or cycloalleles (e.g., cyclopentyl ethers) can also be used in the present invention.
  • acid salts and other pharmaceutically accept ⁇ able substitutions can be used.
  • a particular aspect of the present invention comprises a compound of the present invention in an effective unit dose form.
  • effective unit dose is meant a predetermined amount sufficient to bring about the desired cholesterol inhibitory effect, including inhibition of uptake, synthesis and/or accumulation of cholesterol in vivo, in si tu and in vi tro, which unit dose form can be readily determined by one skilled in the art.
  • the dosage of the compounds of the present invention or their pharmaceutically acceptable salts or derivatives will depend, of course, on the degree of cholesterol inhibition desired. Dosages of pharmaceutically active compounds such as those of the present invention are conventionally given in amounts sufficient to bring about the desired inhibition of cholesterol uptake, synthesis or accumulation, relative to the condition being treated (e.g., arteriosclerosis, atherosclerosis, hypertension, hypothyroidism, obstructive jaundice, nephrosis, diabetes mellitus, pancreatitis, multiple myeloma, porphyria and obstructive liver disease) without causing undue burden on the treated subject.
  • arteriosclerosis e.g., arteriosclerosis, atherosclerosis, hypertension, hypothyroidism, obstructive jaundice, nephrosis, diabetes mellitus, pancreatitis, multiple myeloma, porphyria and obstructive liver disease
  • Compounds of the present invention according to formula (I) can be administered to a subject in amounts preferably ranging from about 0.1 to 3.0 mg/kg per day orally, parenterally, subcutaneously, intramuscularly, intraveneously or as a dermal patch.
  • oral administration is preferably 0.1 to 2 mg/kg, and more preferably, 0.2 to 0.6 mg/kg, 0.7 to 1.2 mg/kg or 1.3 to 1.8 mg/kg, per day.
  • Oral administration can require a higher dosage than intravenous administra io: -1 , due to loss in the digestive tract.
  • Parenteral administration is preferably 0.1 to 3 mg/kg, and more preferably 0.2 to 0.3 mg/kg, 0.4 to 0.7 mg/kg, 0.8 to 1.2 mg/kg, 1.4 to 1.7 mg/kg, 2.0 to 2.5 mg/kg or 2.6 to 2.9 mg/kg, per day.
  • Dermal patch administration is preferably 0.1 to 2.0 mg/kg, and more preferably 0.15 to 0.3 mg/kg, 0.5 to 0.8 mg/kg, or 1.0 to 1.5 mg/kg per day.
  • compositions of the present invention which composition comprises a compound according to formula (I) .
  • Animals, in the context of the present invention include mammals birds and fish, and mammalian use includes use, e.g., in rodents, livestock, primates, horses, dogs, cats and humans.
  • Pharmaceutical preparations including a compound of the present invention according to formula (I) can be administered as a solid or liquid, or as an injectable preparation, in combination with suitable pharmaceutical carriers.
  • suitable pharmaceutical preparations include tablets, capsules, oral liquid, intravenous and parenteral injectables and other equivalent means of administration.
  • the compound is administered as an oral liquii or intravenous glucose solution al using conventional diluents and excipients, wherein the 26-amino furostene has been solubilized in cyclo- dextrin, as presented herein.
  • Intravenous and parenterally administered compositions according to the present invention may be given in combination with conventional injectable liquid carriers such as sterile pyrogen-free water, cyclodextrins, sterile peroxide-free ethyl oleate, dehydrated alcohol, or propylene glycol.
  • conventional injectable liquid carriers such as sterile pyrogen-free water, cyclodextrins, sterile peroxide-free ethyl oleate, dehydrated alcohol, or propylene glycol.
  • Conventional pharmaceutical adjuvants for injection solution such as stabiliz ⁇ ing agent, solubilizing agents and buffers, such as cyclodextrin, ethanol, complex forming agents such as ethylene diamine tetraacetic acid, tartrate and citrate buffers, and high-mole ⁇ cular weight polymers such as polyethylene oxide for viscosity regulation may be added, with cyclodextrin, wherein 2-hydroxy ⁇ propyl - ⁇ - and 2-hydroxypropyl -y-cyclodextrins are preferred.
  • the cyclodextrin can be provided as 20-60% cyclodextrin aqueous solution containing 0.1-30 mg/ml of stably solubilized aminofurostene compounds of the present invention, such that the solution can be diluted to the apporp- riate dosage concentration prior to administration.
  • Such compositions may be administered intramuscularly, subcutaneously, a intraperitoneally, intravenously, or from a dermal patch.
  • carriers and diluents include albumin and/or other plasma protein components such as low density lipoproteins, high density lipoproteins and other lipids and lipoproteins with which these serum proteins are associated.
  • lipids can include phosphatidyl choline, phosphatidyl serine, phosphatidyl ethanolamine and neutral lipids such as triglycerides.
  • Lipid carriers also include, without limitation, tocopherol and retinoic acid.
  • compositions of the present invention may also be formulated into orally administrable compositions containing one or more physiologically compatible carriers or excipients, and may be in solid or liquid in form.
  • compositions may, if desired, contain conventional ingredients such as binding agents, for example, syrups, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, such as lactose, mannitol, starch, calcium phosphate, sorbitol, cyclodextran, or methylcellulose; lubricants such as magnesium stearate, high molecular weight polymers such as polyethylene glycols, high molecular weight fatty acids such as stearic acid or silica; disintegrants such as starch; and acceptable wetting agents as, for example, sodium lauryl sulfate.
  • binding agents for example, syrups, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone
  • fillers such as lactose, mannitol, starch, calcium phosphate, sorbitol, cyclodextran, or methylcellulose
  • the oral compositions may assume any convenient form, such as tablets, capsules, lozenges, aqueous or oily suspensions, emulsions, or dry products suitable for reconstitution with water or other liquid medium prior to use.
  • the liquid oral forms are preferred and may, of course, contain flavors, sweeteners, preservatives such as methyl or propyl p-hydroxybenzoates; suspending agents such as sorbitol, glucose or other sugar syrup, methyl, hydroxymethyl, or carboxymethyl celluloses or gelatin; emulsifying agents such as lecithin or sorbitan monooleate or thickening agents.
  • Concentrated oral forms are also preferred, wherein 20-60% cyclodextrin aqueous solutions containing 0.2-30 mg/ml solubilized aminofurostene compounds of the present invention, such that the concentrate can be diluted to the appropriate dosage concentration prior to administration.
  • Non-aqueous compositions may also be formulated which comprise edible oils as, for example, fish-liver or vegetable oils. These liquid compositions may conveniently be encapsulated in, for example, gelatin capsules in a unit dosage amount.
  • compositions according to the present invention may also be administered, if appropriate, either topically as an aerosol or, formulated with conventional bases as a cream or ointment.
  • compositions of the present invention can also be administered by incorporating the active ingredient into colloidal carriers, such as liposomes.
  • colloidal carriers such as liposomes.
  • Liposome technology is well known in the art, having been described by Allison et al. in Nature 252: 252-254 (1974) and Dancy et al. , J. Immunol. 120: 1109- 1113 (1978) .
  • active-targeting vesicles can be used as carriers for the active components of the present invention by placing a recognition sequence, i.e., from an antibody, onto the vesicles such that it is taken up more rapidly by certain cell types which are known to uptake, synthesize, store or accumulate cholesterol (cf. Papahadjopoulou et al. , Annals of the New York Academy of Sciences, 507: 67-74 (1987)).
  • the active components can be adminis ⁇ tered in the form of sustained release products, by incorporating the active components in a suitable polymer.
  • Polymer systems found to be useful in delivering compounds according to formula (I) of the present invention in a time-dependent manner are known in the art and include subdermal reservoir implants composed of non-degradable polymers that release steroids for extended periods of time (Folkman et al . , J. Sur . Res. 4: 139 (1964) , entirely incorporated by reference) and subdermal implants or injectable microspheres comprising degradable materials, such as lactide-glycoside copolymers and polycaprolactones (Langer, Science 249: 1527-1532 (1990) entinrely incoporated by reference) .
  • degradable materials such as lactide-glycoside copolymers and polycaprolactones
  • cyclodextrin is preferred, as presented herein, due to the suitable solubility and and lack of toxicity using cyclodextrin, such as ⁇ - and 7-cyclodextrin are preferred and wherein 2-hydroxy - ⁇ -cyclodextrin and 2-hydroxy-7-cyclodextrin are especially preferred.
  • compositions of the present invention may be administered in conjunction with, as well as formulated with, at least one other therapeutic agent to produce a combination composition and/or therapy effective for ameliorating certain elevated cholesterol pathologies, e.g., arteriosclerosis, atherosclerosis, hyperten- sion, hypothyroidism, obstructive jaundice, nephrosis, diabetes mellitus, pancreatitis, multiple myeloma, porphyria and obstruc ⁇ tive liver disease.
  • certain elevated cholesterol pathologies e.g., arteriosclerosis, atherosclerosis, hyperten- sion, hypothyroidism, obstructive jaundice, nephrosis, diabetes mellitus, pancreatitis, multiple myeloma, porphyria and obstruc ⁇ tive liver disease.
  • compositions of the present invention may be administered first and other therapeutic agents later, or vice versa.
  • Therapeutic agents include, by way of non-limiting examples, cardiac glycosides, antidysrythmics, diuretics, antihypertensives, antianginals, anticoagulants, and lipid lowering agents.
  • Sucn agents are well known in the art and the use of such drugs in connection with a pharmaceutical composition of the present invention can be accomplished by one of ordinary skill in the art using routine experimentation, based on the teachings and guidance presented herein.
  • 26-amino-furost-5-en-3/3-ol was prepared by lithium aluminum hydride (LAH) reduction of diosgenin to form 26-amino-furost-5-en-3/3-ol, followed by substitution of the
  • 26-hydroxyfurost-5-ene-3/3-ol was prepared by lithium aluminum hydride reduction of Diosgenin, followed by formation of an acetate of the 3/3-ol by reaction with trityl to form 26-0-trityl-furost-5-ene-3/3-ol, followed by reaction with the 26-0-trityl with acetic anhydride to form 26-0-trityl-furost-5-ene-3-acetate and reaction of the 3-acetate with HCl/ethanol to form 26-hydroxyl-furost-5-ene-3-acetate.
  • 26 amino-furost-5-ene-3-jSol was then formed by reacting the 26 hydroxy-furost-5-ene-3-acetate with proylchloride to form 26 - tosyl - furost - 5 - ene- 3 acetate .
  • 26-Tosylfurost-5-ene-3-acetate (0.66 mmol) was dissolved in 25 ml of DMF containing 1.5 equiv. of NaN 3 and 1 ml of water. The solution was heated to between 90 and 100°C for 2 h, cooled to room temperature and then worked up as usual. Rotary evaporation yield (yield > 80%) of 26-azidocholesterol 3-acetate as a white powder, which was subsequently recrystallized (with ethanol) to yield white waxy crystals.
  • 26-aminofurost-5-ene-3/3-ol is purified usings a capillary gas liquid chromatography using a Shimadzu 14-a capillary GLC using WCOT fused silica cp-sil-5-CB having a 50 meter lenght a 2.25 mm I.D., a 0.39 O.D. and a 0.12 micromfilm thickness, at a flow carrier rate of 1.5 mils per minute of helium with a temperature program of 265 initial with 1 °C/min raised 285 °C/min raised to 1 °C/min raised to 285 °C. Peak 2 was found to be th 26 amino furost-5-ene-3/3-ol with a 96.4% purity and a elution time of 23.742 minutes.
  • HepG2 Cells were obtained from Dr. Barbara Knowles of the Wistar Institute, Pennsylvania, and are readily available from commercial sources, e.g., the ATCC in Rockville, Maryland.
  • Stock HepG2 monolayers were maintained in T-75 disposable Nunc flasks, in a medium comprising 10 ml of DMEM (Dulbecco's Eagle's Minimum Essential Medium with Earl's salts, pH 7.4) supplemented with 10% (v/v) fetal bovine serum (FBS) and human serum plasma, 2% (v/v) non-essential and essential amino acids, 1% (v/v) DMEM vitamins, 1% L-glutamine (292 ug/ml) , 1% penicillin (100 U/ml) -streptomycin (100 ug/ml) .
  • the HepG2 stock was maintained at 37°C. in a humidified atmosphere of 5% C02 and 95% air. The medium was routinely changed every 3-4 days and the cells were passaged
  • the hepatoblastoma cells were cultured in media containing 25% D20 and 1% FBS in order to determine de novo cholesterol synthesis under conditions that permit receptor mediated cholesterol transport, according to the method of Easterman & Javitt et al J. Lipid Res. 26:950-954 (1985) . Dish cultures of each cell type were prepared, and 26-amino-f ⁇ rost-5-en-33-ol, dissolved in N,N-dimethylformamide (DMF, 9 ⁇ l per dish, 0.3% v/v) was added to each culture.
  • DMF N,N-dimethylformamide
  • D 2 0 was used during all cholesterol synthesis, provided as 15% of the growth medium. After this incubation, the culture dishes were placed on ice, the medium was removed, and the cell monolayers were washed as described in Goldstein & Brown J. Biol. Chem. 249:5153-5162 (1974) .
  • Free cholesterol was then quantified by g.l.c. on a Perkin-Elmer capillary gas-liquid chromatograph (model 8320) fitted wiht a 20 mDe-1 methylsilicone glass column (Supelco) . The remaining extract was dried and saponified with 2% ethanolic KOH at 80°C for 1 hr. The sterols were then re-extracted, and total cholesterol was measured by g.l.c. ar ' ter silylation. Cholesterol ester was calculated as the difference between total and free cholesterol determinations. Newly synthesized choles ⁇ terol was quantified by a g.l.c.-.s.
  • a pharmaceutical composition containing 26-amino-furo- st-5-en-3/3-ol was prepared as a stable aqueous solution having a maximum solubility of 20 mg/ml in a 45% aqueous solution of 2-hydroxypropyl- ⁇ -cyclodextrin.
  • 26-amino-furost-5-en-3/3-ol prepared, e.g., as presented in Example 1 above, was added to provide a final concentration of 20 mg/ml in a sterile 45% aqueous solution of 2-hydroxypropyl - ⁇ -cyclodextrin and left standing for 24 hours, which was then suitable for administration to a subject in by diluting to an appropriate concentration.
  • Cyclodextrins are well known to be safe for administration to mammals and birds. Additionally, the present composition was also found to lack toxic effects when given in a range of concentrations of up to about 45 mg/kg of an aminofurostene of the present invention, as 26-amino-furost-5-en- i ⁇ - ol (e.g., 5 mg dose to a llOg hamster) .
  • the above 20 mg/ml composition is added in the amount of 1 ml to 1 liter of a 5% glucose IV solution and administered intravenously over a period of approximately 24 hours (e.g., 1 mg per hour or about 0.25-0.3 mg/kg per day) for 3-7 days following cardiac acidy, such as angioplasty.
  • the administra ⁇ tion of 26-aminofurostene compounds according to the present invention is useful for inhibiting the uptake, synthesis and/or accumulation of cholesterol and thus is helpful for keeping cardiac arteries from additional or re-accumulation of cholester ⁇ ol related or unrelated to corrective cardiac surgery, such as angioplasty.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Sont décrits des 26-aminofurostènes, et notamment des compositions et des procédés pour fabriquer et utiliser ces composés, selon la formule (I), dans laquelle (a) R1 est hydroxy ou céto, de sorte qu'au moins un élément parmi C3 et C4 et C4 et C5 forment une double liaison lorsque R1 est céto, et que C5 et C6 forment une double liaison lorsque R1 est hydroxy; (b) R2 est soufre, oxygène ou azote; et (C) R3 est un alcool C1-C3, aldéhyde ou acide, ou bien un ester, un éther, un sulfate, un carbonate, un glucoronide, un complexe de cyclodextrine ou bien leur sel.
PCT/US1993/007810 1992-08-21 1993-08-19 Aminofurostenes, compositions, et procedes d'utilisation WO1994004556A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU50815/93A AU5081593A (en) 1992-08-21 1993-08-19 Aminofurostenes, compositions, and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93220192A 1992-08-21 1992-08-21
US932,201 1992-08-21

Publications (1)

Publication Number Publication Date
WO1994004556A1 true WO1994004556A1 (fr) 1994-03-03

Family

ID=25461937

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/007810 WO1994004556A1 (fr) 1992-08-21 1993-08-19 Aminofurostenes, compositions, et procedes d'utilisation

Country Status (3)

Country Link
CN (1) CN1087091A (fr)
AU (1) AU5081593A (fr)
WO (1) WO1994004556A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998047518A1 (fr) * 1997-04-17 1998-10-29 Europäisches Laboratorium für Molekularbiologie (EMBL) Utilisation d'agents hypo-cholesterolemiants pour influer sur les processus de transduction de signaux au niveau de la membrane cellulaire, dans le cadre de la prophylaxie ou du traitement de maladies associees aux prions ou de la maladie d'alzheimer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2740781A (en) * 1954-07-06 1956-04-03 Searle & Co 3, 26-dihydroxy-16, 22-imino-5-cholestenes, 3, 26-dihydroxy-16, 22-imino-5, 16, 20(22)-cholestatrienes and derivatives thereof
WO1990003171A1 (fr) * 1988-09-19 1990-04-05 New York University 26-aminocholesterol ainsi que derives et analogues de ce compose utilises dans la regulation de l'accumulation de cholesterol dans les tissus corporels
WO1991010743A1 (fr) * 1990-01-18 1991-07-25 Cura Nominees Pty Ltd Glycoalcaloides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2740781A (en) * 1954-07-06 1956-04-03 Searle & Co 3, 26-dihydroxy-16, 22-imino-5-cholestenes, 3, 26-dihydroxy-16, 22-imino-5, 16, 20(22)-cholestatrienes and derivatives thereof
WO1990003171A1 (fr) * 1988-09-19 1990-04-05 New York University 26-aminocholesterol ainsi que derives et analogues de ce compose utilises dans la regulation de l'accumulation de cholesterol dans les tissus corporels
WO1991010743A1 (fr) * 1990-01-18 1991-07-25 Cura Nominees Pty Ltd Glycoalcaloides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
G. KUSANO ET AL: "Solanum Alkaloids as Inhibitors of Enzymatic Conversion of Dihydrolanosterol into Cholesterol", CHEMICAL AND PHARMACEUTICAL BULLETIN., vol. 35, no. 10, October 1987 (1987-10-01), TOKYO JP, pages 4321 - 4323 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998047518A1 (fr) * 1997-04-17 1998-10-29 Europäisches Laboratorium für Molekularbiologie (EMBL) Utilisation d'agents hypo-cholesterolemiants pour influer sur les processus de transduction de signaux au niveau de la membrane cellulaire, dans le cadre de la prophylaxie ou du traitement de maladies associees aux prions ou de la maladie d'alzheimer

Also Published As

Publication number Publication date
AU5081593A (en) 1994-03-15
CN1087091A (zh) 1994-05-25

Similar Documents

Publication Publication Date Title
ES2307819T3 (es) 17alpha-alquil-17beta-oxy-estratrienos y productos intermedios para supreparacion, utilizacion de los 17alpha-alquil-17beta-oxy-estratrienospara la preparacion de medicamenteos, asi como formulaciones farmaceuticas.
JP6125610B2 (ja) 代謝障害、高脂血症、糖尿病、脂肪性肝疾患及びアテローム性動脈硬化症の治療のための新規コレステロール代謝物、５−コレステン−３β，２５−ジオールジスルファート（２５ＨＣＤＳ）
JP2002255993A (ja) ステロイドスルファターゼインヒビター
JP2006506445A (ja) 治療処置の方法
US4265823A (en) Aurothiosteroids
JP2002145891A (ja) ステロイドスルファターゼインヒビター
JPH09501433A (ja) 抗−分裂剤としてのエストロゲン性化合物
JP2000501732A (ja) 抗炎症薬として有用な新規ステロイドナイトライト／ナイトレートエステル誘導体
US7985774B2 (en) Use of 3,5-seco-4-nor-cholestane derivatives for obtaining a cytoprotective drug
JP2000509072A (ja) 抗炎症剤として有用な新規ステロイド亜硝酸エステルおよび硝酸エステル誘導体
Sutanto et al. Mineralocorticoid receptor ligands: biochemical, pharmacological, and clinical aspects
EP1890705B1 (fr) Utilisation d'acide 24-nor-ursodesoxycholique dans le traitement de maladies choléstatiques hépatiques
US4464388A (en) Use of prostaglandin analogues to treat cytodamage
Nadeson et al. Antinociceptive properties of neurosteroids III: experiments with alphadolone given intravenously, intraperitoneally, and intragastrically
US20130281419A1 (en) Therapeutic Uses for an Aminosterol Compound
EP0393180B1 (fr) 26-aminocholesterol ainsi que derives et analogues de ce compose utilises dans la regulation de l'accumulation de cholesterol dans les tissus corporels
US4503068A (en) Use of prostaglandin analogues to treat cytodamage
ZA200210214B (en) Neuroprotective 7-beta-hydroxysteroids.
EP0814792A1 (fr) Derives de mercapto et seleno inhibiteurs de la synthase de l'oxyde nitrique
KR960002913B1 (ko) 아미노알킬 측쇄를 갖는 사이클릭 탄화수소
JP2765822B2 (ja) 酸化防止作用を有するステロイドを含有する、ヒトにおける薬物ホルモン代用のための製薬学的調剤
CZ20012341A3 (cs) Kombinace inhibitorů transferoního proteinu cholesterylesterů a derivátů kyseliny fibrové pro kardiovaskulární indikace
WO1994004556A1 (fr) Aminofurostenes, compositions, et procedes d'utilisation
US20030232797A1 (en) Novel derivatives of androstane and androstene with ascorbic acid and use thereof in treating or preventing various conditions, diseases, and disorders
US5376652A (en) Administration of a 27-hydroxycholesterol or related compound or sterol-27-hydroxylase stimulant to prevent restenosis following vascular endothelial injury

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA GB JP KP KR

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA